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The characteristics of unsolicited
clinical oncology literature
provided by pharmaceutical
industry
The pharmaceutical industry plays an important role in the
development of new cancer treatments. Data from clinical
phase I to III trials will, if convincing, eventually lead to
the licensing of the drug. At that stage, and even before,
companies embark on marketing and promotion of their
new products [1, 2], by advertising in professional journals,
through visits by drug company representatives, the
organization of promotional meetings or sponsoring of
continuous medical education. Finally, many drug
companies maintain promotional mailing services to
physicians to provide them with regular information,
particularly on new drugs. Concern has been voiced that
advertising may lead to uncritical and inappropriate
prescribing of new drugs in clinical practice [3]. Articles
prepared with drug company support have been shown to
be more likely to report favourably on a drug of interest
than articles published without such support [4]. In
advertisements for antihypertensive and lipid-lowering drugs
in Spanish medical journals, the promotional statement was
not supported by the studies cited in 40%, most frequently
because the advert recommended the drug in a patient group
other than that assessed in the respective trial [5]. Drug
companies may exert a considerable influence over which
drugs doctors prescribe [6], and also influence continuous
medical education. A recent letter to the Annals of Oncology
pointed out that visits of pharma representatives in clinical
departments are increasing apparently with the aim of
pushing clinicians towards using their specific drugs [7–9].
Whereas the relationship and interactions between doctors
and drug company representatives and the advertising
practices of industry have been examined in several studies
[5, 10, 11], promotional mailings have not been analysed in
depth. We studied the characteristics of literature and other
material mailed by the pharmaceutical industry to a medical
oncologist in Switzerland.
One of us (MFF) prospectively and comprehensively
collected all unsolicited mail posted to his hospital address
from pharmaceutical companies from 1st January to 30th
September 2002. We classified the material as follows: (i)
peer-reviewed journal articles (reprints of original research
or reviews), (ii) abstracts from peer-reviewed articles, (iii)
customized abstracts, (iv) lists of references and (v)
publications prepared by industry or communication
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companies working for industry. The latter consisted of
newsletters or conference reports, for example editorials
written by opinion leaders, reviews prepared by industry and
interviews with keynote speakers. Abstracts published in
journals or conference proceedings that had been rewritten
or edited by industry were classified as customized abstracts.
We assessed whether in material reporting on clinical trials
of anticancer drugs, results were interpreted as showing
superiority or inferiority of the new drug, or no difference
between comparison groups. Statements such as ‘‘new
treatment offers significant improvement over .’’, ‘‘new
drug significantly better .’’, etc. were interpreted as
indicating superiority.
Forty-nine mailings including a total of 961 items from 13
different pharmaceutical companies were received during the
study period (1.25 mailings and 24.6 items per week). The
vast majority of items received were customized abstracts
(768, 80%; Table 1). Thirty items were original abstracts
(3%) and seven (0.7%) were reprints of articles published in
peer-reviewed journals. A total of 156 items (16.3%) were
from industry newsletters or conference reports. Among the
805 items selected from the literature and conference
proceedings, reports on clinical trials (276 items, 28.7%) and
narrative review articles (271 items, 28.2%) were most
common. Among clinical trials, phase II studies (125, 46%)
were more frequently included than phase III (95, 34%) and
phase I studies (56, 20%). Only 12 (1.2%) items reported on
systematic reviews. The drugs most frequently examined in
the 220 phase II and phase III studies were tamoxifen,
anastrozole and docetaxel. Head-to-head comparisons of
different drugs were reported in 120 (55%) items (86 phase
III and in 34 phase II clinical trials). The remaining articles
compared different dosages of the same drug in dose-finding
studies or the effect of different numbers of treatment cycles.
A total of 173 reports of phase II and III trials (79%)
reported results that favoured the drug produced by the
company responsible for mailing the item (Table 2).
Most of them reported unpublished data from meeting
abstracts.
Although our study was based on the mail received by one
Swiss medical oncologist, we assume that the material was
representative of what was mailed to many, if not all,
practising oncologists in Switzerland during the sampling
period as a part of mass mailings. Mailings were frequent
and mainly included abstracts of unpublished studies
presented at conferences, which were often edited (customized)
by industry. Clinical trials and narrative reviews dominated,
whereas systematic reviews were virtually absent. Among
phase II and phase III drug trials, a large majority of items
reported results that were favourable to the drug produced
by the company sending the material. An interesting finding
of our study is the frequent use of customized, rewritten
or edited, abstracts. Their content was often simplified,
and data presented in more appealing ways, for example
by using colour graphs rather than tables. Clearly, further
research is needed to clarify whether and in what way
content and conclusions may have changed in this process.
Many practising physicians value promotional efforts of
pharmaceutical companies to communicate data on new
drugs with possible relevance to their daily clinical work.
Company-based promotion is highly organized and
allegedly comprehensive, as evidenced, for example, by the
inclusion of reference lists in the mailings examined in this
study. The selection of the abstracts included in themailings may
well have favoured the company’s drugs, similar to the well-
documented selective publication of positive results [12].
Furthermore, the majority of the items related to conference
presentations of unpublished studies. Meeting abstracts
represent preliminary, immature and incomplete
communications of clinical data. Their validity is therefore lower
than that of peer-reviewed original articles published in scientific
journals [13]. The conclusions published in meeting abstracts do
not always match the conclusions from the corresponding
original article that is typically published in peer-reviewed
journals 1–2 years later. Finally, unsystematic narrative reviews
of published evidence often reach erroneous conclusions, and
systematic reviews and meta-analyses, which are based on
comprehensive literature searches and careful assessment of the
quality of component studies are more reliable [14]. The clear
focus on narrative reviews in the material sent to oncologists
Table 1. Types of studies and articles selected by industry for mailing
from the literature and conference proceedings
Design Type of article
Peer-
reviewed
journal
article
Original
abstract
Customized
abstract
Total
Clinical trial 2 27 247 276 (28.7%)
Phase I 0 6 50 56
Phase II 1 16 108 125
Phase III 1 5 89 95
Narrative review 2 2 267 271 (28.2%)
Systematic review 0 0 12 12 (1.2%)
Cohort study 2 0 67 69 (7.2%)
Case–control study 0 0 28 28 (2.9%)
Case series 1 1 85 87 (9.1%)
Case report 0 0 28 28 (2.9%)
Laboratory study 0 0 22 22 (2.3%)
Economic study 0 0 12 12 (1.2%)
Subtotal including
scientific articles
7 (0.7%) 30 (3%) 768 (80%) 805 (83.7%)
Total 961 (100%)
Table 2. Conclusions from phase II and III drug trials selected by
industry
Type of trial
Phase II Phase III Total
Experimental drug
Less beneficial 8 (6.5%) 11 (11.5%) 19 (8.5%)
More beneficial 105 (84%) 68 (72%) 173 (79%)
Equivalent 8 (6.5%) 11 (11.5%) 19 (8.5%)
No clear statement 4 (3%) 5 (5%) 9 (4%)
Total 125 (100%) 95 (100%) 220 (100%)
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must therefore be of concern, and represents another potential
source of bias.
We found that 80% of clinical trials were interpreted as
showing superiority of the drug produced by the company
mailing the item on the trial. In addition to the selective
inclusion of positive studies, the inclusion of trials of low
methodological quality, which tend to exaggerate effects, is
another element of concern [15, 16]. Trials may be designed
to produce positive results, for example by using
comparison treatments that are known to be substandard.
Such trials violate the uncertainty principle: patients
should be enrolled in randomized clinical trials only, if
there is substantial uncertainty about the efficacy of the
treatments being compared. A recent survey of randomized
clinical trials in patients with multiple myeloma [17] found
that overall the uncertainty principle was upheld, with 56%
of trials favouring experimental treatments and 44%
standard treatments. However, this was not the case for
studies funded by industry, which favoured the experimental
drug in 74% of trials.
The material received during the study period mainly
included literature about a restricted and selected number
of newer drugs that were being heavily promoted during
the study period. Articles addressing other important
questions in oncology, including for example advances in
the multidisciplinary treatment of cancer, and other
important issues of interest were conspicuously under-
represented in the collected material.
In summary, we conclude that mailed educational
material provided by pharmaceutical companies appears to
be biased to include selected positive data and trials on drugs
of timely interest to the respective company. Although
literature services of pharmaceutical companies offer much
convenience, physicians should not rely on unsolicited
literature when reviewing the evidence of the clinical efficacy
and safety of new drugs. Doctors should be aware of the
possible biases involved, review such material critically and
consider its implications for their continuous medical
education as well as their treatment decisions in clinical
practice.
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